Why LGND beats the market
Up 394% over three years while the S&P 500 rose 58%.
- Its operating margin went from 1.5% in fiscal 2022 to 15.3% in fiscal 2025; its 2 peers' median rose 6.0 points.
Follow LGND's news. Pro members can get an alert when Ligand Pharmaceuticals files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Up 394% over three years while the S&P 500 rose 58%.
| The chart | Stronger than 90% of stocks |
| Latest filing | 10-Q, Oct 30 |
Expected to report Thu Feb 25, before the open
Director Martine Zimmermann sold 2,000 shares on Nov 12. 30 more insider trades this year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
Averagefor quality, not price, 2 of 14 chart checks firingWhat the Quality Score means
Well below its recent run. LGND scores 8 today, against a median of 15 over its last 20 recorded sessions.
LGND is #40 of 273 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 40 |
Expected to report Thu Feb 25, before the open (in 96 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
A loss of $1.43 a share, from a profit of $5.68.
“Royalties accounted for 89% of total revenues and income in the quarter, with growth driven by the newly acquired XOMA assets and continued momentum across Ligand’s key commercial portfolio, including Travere Therapeutics’ Filspari and Merck’s Ohtuvayre.”
| Line | Q3 2026 | Q2 2026 | Q3 2025 |
|---|---|---|---|
| Royalty | $70.3M | $48M | $46.6M |
Each quarter's sales and their share of its total. Figures as filed (SEC filing, Oct 30)
| Measure | Figure |
|---|---|
| Adjusted earnings per diluted share | $9.50 to $9.75 |
“The decreases were primarily attributable to the $24.5 million of Pelthos out-license income recognized in the prior-year period (see Pelthos note below) and higher general and administrative expense excluding share-based compensation and transaction and integration costs, partially offset by the 51% increase in royalty revenue.”
From its results filing (SEC filing · Oct 29)
Sales grew 10% a year over 5 years, fiscal 2020 to 2025.
Its share count grew 3.8% a year over 5 years.
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Oct 29, 2026 | -1.1% | -0.5% | -0.8% |
| Aug 6, 2026 | +1.2% | -0.8% | -3.1% |
| May 7, 2026 | -11.8% | -9.6% | -4.9% |
Sales grew in four of the last seven years, to $268M in 2025. It turned a profit in 2025 after a loss in 2024.
RSI 38.8, MACD below signal, below its 50-day, above its 200-day. Not scored.
5 insiders sold $9.4M across 25 filings in the last 6 months. No open-market buys on record. The newest:
2 trades disclosed in the last six months. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: LGND is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
“Some of the drugs we and our licensees and partners are developing may compete with existing therapies or other drugs in development by other companies.”
LGND scores 8 today, which Breakaway calls Average. It is #40 of 273 in Biotech by Quality Score, with 2 of 14 chart checks firing. Up 394% over three years while the S&P 500 rose 58%. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
LGND scores 8 today, which Breakaway calls Average (6 to 10). That is #40 of 273 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind LGND's 8.
5 insiders sold $9.4M across 25 filings in the last 6 months. No open-market buys on record. The newest is Martine Zimmermann, Director, who sold $636K on Nov 12. Every filing, with the scored weight, for Pro members.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Only on the public pages, which run at least 15 minutes behind. Pro members see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included. The one stock you open in full is live too.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.